Predictive value of DNA methylation patterns in AML patients treated with an azacytidine containing induction regimen
Acute myeloid leukemia (AML) is a heterogeneous disease with a poor prognosis. Dysregulation of the epigenetic machinery is a significant contributor to disease development. Some AML patients benefit from treatment with hypomethylating agents (HMAs), but no predictive biomarkers for therapy response...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
26 October 2023
|
| In: |
Clinical epigenetics
Year: 2023, Volume: 15, Pages: 1-16 |
| ISSN: | 1868-7083 |
| DOI: | 10.1186/s13148-023-01580-z |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s13148-023-01580-z Verlag, kostenfrei, Volltext: https://clinicalepigeneticsjournal.biomedcentral.com/articles/10.1186/s13148-023-01580-z |
| Author Notes: | Maximilian Schmutz, Manuela Zucknick, Richard F. Schlenk, Daniel Mertens, Axel Benner, Dieter Weichenhan, Oliver Mücke, Konstanze Döhner, Christoph Plass, Lars Bullinger and Rainer Claus |
| Summary: | Acute myeloid leukemia (AML) is a heterogeneous disease with a poor prognosis. Dysregulation of the epigenetic machinery is a significant contributor to disease development. Some AML patients benefit from treatment with hypomethylating agents (HMAs), but no predictive biomarkers for therapy response exist. Here, we investigated whether unbiased genome-wide assessment of pre-treatment DNA-methylation profiles in AML bone marrow blasts can help to identify patients who will achieve a remission after an azacytidine-containing induction regimen. |
|---|---|
| Item Description: | Gesehen am 05.03.2024 |
| Physical Description: | Online Resource |
| ISSN: | 1868-7083 |
| DOI: | 10.1186/s13148-023-01580-z |